Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections.
Frontiers in immunology（2023）
摘要
Tixagevimab/cilgavimab provided a comparable neutralizing activity against the BA.5 with a healthy adult population who were vaccinated with a 3 shot and experienced BA.1/BA.2 BI.
更多查看译文
关键词
BA.5 variant,COVID-19,Evusheld,SARS-CoV-2,neutralizing antibody
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要